The National Institute for Health and Clinical Excellence has published an amended version of its technology appraisal of drugs to treat Alzheimer's disease to fully comply with the judge's ruling on the judicial review issued last month.

NICE has clarified how the guidance should be applied to certain groups, including people with learning disabilities and people whose first language is not English.